SEATTLE, Wa., August 19, 2015 – Adaptive Biotechnologies, the leader in next generation sequencing (NGS) to profile T- and B-cell receptors of the adaptive immune system, announces a publication in Science Translational Medicine on a novel first-in-class technology for pairing T-cell receptor (TCR) alpha and beta chain sequences at high throughput.
SEATTLE, Wa. – Adaptive Biotechnologies, the leader in next generation sequencing (NGS) to profile T- and B-cell receptors of the adaptive immune system, announced today the appointment of Chad Cohen as its new Chief Financial Officer, effective immediately. Mr. Cohen has served on Adaptive’s Board of Directors since March 2015. Most recently, Mr. Cohen served as CFO for Zillow Group, where he oversaw all finance, treasury and accounting functions and led the finance organization through Zillow's 2011 IPO and nine acquisitions.
Adaptive Biotechnologies today announced the recent publication of a study in JAMA Oncology that demonstrates that measurement of minimal residual disease (MRD) is a critical tool in evaluating response to new highly effective drug combinations for the treatment of multiple myeloma.
Adaptive Biotechnologies, the leader in combining high-throughput sequencing and expert bioinformatics to profile T-cell and B-cell receptors, will present data from a study of more than 400 children with acute lymphoblastic leukemia (ALL), some observed for more than a decade, demonstrating that the company’s immunosequencing platform, available clinically in the United States as the clonoSEQ® Process, can more sensitively detect minimal residual disease (MRD) than flow cytometry, and that MRD detected using this method is predictive of a patient’s ultimate outcome. These data and more will be presented at the 20th Congress of the European Hematology Association in Vienna, Austria, June 11-14, 2015.
Adaptive Biotechnologies announced the publication of a joint study with the Children’s Oncology Group (COG) and Pediatric Blood and Marrow Transplant Consortium (PBMTC) demonstrating that minimal residual disease detected using next-generation sequencing (NGS), available clinically as the clonoSEQ® MRD Test through the company’s CLIA-certified laboratory, can more accurately predict relapse and survival compared to multichannel (6-color) flow cytometry in pediatric acute lymphoblastic leukemia (ALL) patients undergoing donor stem cell transplants.
SEATTLE, Wa., May 29, 2015 – Adaptive Biotechnologies, the leader in next generation sequencing (NGS) to profile T- and B-cell receptors of the adaptive immune system, and its collaborators will present data demonstrating the utility of immunosequencing from tissue and blood in predicting and monitoring response in cancer at the 2015 American Society of Clinical Oncology® (ASCO®) meeting in Chicago from May 29-June 2, 2015.
SEATTLE, WA – Adaptive Biotechnologies, the leader in next generation sequencing (NGS) to profile T- and B-cell receptors, demonstrated in today’s issue of Nature Medicine the ability of the immunoSEQ® Assay to interrogate cell fate in naturally occurring T-cell populations. Contrary to previous thinking, the results show that different types of T cells often descend from a common ancestor. These findings are a groundbreaking advance in the understanding of adaptive immunity and its potential role in pathogenic response.
SEATTLE, WA – Adaptive Biotechnologies, the leader in next generation sequencing (NGS) to profile T- and B-cell receptors of the adaptive immune system, and its collaborators will present data demonstrating how profiling a patient’s T-cell repertoire may lead to diagnostic and therapeutic discovery in immune-mediated diseases at the American Association of Immunologists (AAI) Annual Meeting in New Orleans from May 8-11, 2015.
Adaptive Biotechnologies, a leader and pioneer in next generation sequencing (NGS) of T-cell and B-cell receptors in the immune system, announced today the completion of Adaptive’s Series F financing round with a $195 million investment to support several strategic growth initiatives. This round was led by Matrix Capital Management and included other new investors Senator Investment Group, Tiger Management, Rock Springs Capital and an additional large healthcare investor, alongside participation from existing investors Viking Global, Casdin Capital and Alexandria Real Estate Equities. Adaptive is also backed by industry-leading strategic investors Illumina, Celgene, BD Biosciences and LabCorp.
SEATTLE, WA - Adaptive Biotechnologies today announced the recent publication of a study conducted with researchers at The University of Texas MD Anderson Cancer Center showing that the company’s next-generation sequencing-based approach to identification and quantification of populations of B cells can detect tumor-specific DNA sequences in the blood of people with classical Hodgkin’s lymphoma (CHL).
Immune Profiling in Health and Disease
Join us for this premier conference featuring world-renound immunosequencing thought-leaders. Early registration and abstract submission deadline is July 15th. Sign up today! http://www.nature.com/natureconferences/iphd2015/index.html